Jaypirca (pirtobrutinib) treats BTK-inhibitor–resistant lymphoma by blocking BTK (Bruton’s tyrosine kinase) with a mechanism designed to work even when the cancer has become resistant to earlier BTK inhibitors. [1]
How does Jaypirca keep working after other BTK inhibitors stop?
BTK inhibitors used in lymphoma treatment can stop working when tumor cells develop resistance, including changes in the BTK target that reduce drug binding. Jaypirca is a non-covalent BTK inhibitor, meaning it can inhibit BTK without forming the same type of irreversible (covalent) bond as many first-generation BTK inhibitors. That different binding approach can allow Jaypirca to inhibit BTK signaling in some patients whose lymphoma progressed on prior BTK therapy. [1]
What type of “BTK-inhibitor resistant” disease is it used for?
Jaypirca is used for adult patients with mantle cell lymphoma (MCL) who have received at least two prior therapies, including one prior BTK inhibitor. It is also used for other adult relapsed or refractory B-cell lymphomas, depending on the approved indication, including patients whose disease progressed after BTK inhibitor treatment. [1]
What happens biologically when BTK is blocked in these tumors?
BTK is part of B-cell signaling pathways that help lymphoma cells survive and proliferate. By inhibiting BTK, Jaypirca reduces those survival/proliferation signals, which can shrink tumors and control disease in resistant cases. [1]
What to know about resistance and response expectations
“BTK-inhibitor resistant” does not mean the tumor is resistant in only one way; different resistance mechanisms can affect how well any BTK-targeting drug works. Jaypirca’s non-covalent BTK inhibition is designed to address some resistance patterns seen after covalent BTK inhibitors, but individual responses still vary by patient and prior treatment history. [1]
Sources
[1] https://www.drugpatentwatch.com/p/jaypirca-pirtobrutinib